February 3, 2026

Hiring Manager
Eli Lilly

Re: Senior Risk Analytics Leader

I am writing to express my strong interest in the Senior Risk Analytics Leader position within Lilly's Integrated Risk Management Insights Hub. With over 9 years of pharmaceutical experience architecting production analytics solutions, influencing executive decision-making, and applying advanced machine learning to regulatory intelligence and risk detection, I am excited about the opportunity to co-own IRM's technical architecture and transform how Lilly identifies and mitigates enterprise risk.

My current work at Redica Systems aligns directly with IRM's mission and technical requirements. I architect production analytics solutions for pharmaceutical clients including Eli Lilly, serving as technical owner for an FDA Form 483 regulatory intelligence platform that identifies emerging compliance risks through automated monitoring. I designed and deployed a production LLM classifier using the OpenAI API that reads unstructured enforcement text and assigns severity levels and risk categories, owning the entire solution from prompt engineering through validation frameworks and production accuracy monitoring. This work demonstrates my ability to move seamlessly between sophisticated technical development and strategic business value, which is central to the IRM role.

I have consistent experience translating complex architectures into executive strategy and influencing C-suite decision-making. At Gilead, I co-owned the enterprise data analytics roadmap for Medical Affairs, presenting strategic recommendations to VP-level leadership and architecting a centralized data lake with governance frameworks that improved data quality by 40%. At Takeda, I presented data-driven insights during semi-annual APQR meetings to C-suite executives, translating sophisticated analytics into risk mitigation priorities. At Regeneron, my feed optimization project findings changed business decisions at the senior leadership level. I have also delivered solo presentations at major industry conferences (CHPA, ISPE) on AI/ML applications in FDA-regulated industries, demonstrating thought leadership and the ability to represent technical capabilities in enterprise forums.

My technical depth spans the modern data stack required for IRM's analytics architecture. I have hands-on production experience with Snowflake and Databricks, building lakehouse architectures with medallion patterns, CI/CD pipelines, and data governance frameworks. I am proficient in Python, SQL, and advanced analytics, having built production machine learning models using scikit-learn, PyTorch, and ensemble methods for risk detection, classification, and time series forecasting. While I have extensive Spotfire expertise (system administrator at Takeda), I am eager to expand into Power BI and Microsoft Fabric, and my rapid learning agility and continuous improvement mindset position me to quickly master these technologies.

I bring deep pharmaceutical domain expertise from Regeneron, Takeda, and Gilead, with sophisticated understanding of FDA-regulated environments, quality analytics, and compliance requirements. My PhD in Mathematics focused on optimization and control of complex systems using multi-objective algorithms, providing strong quantitative foundations for sophisticated risk modeling. I am passionate about technical excellence, hands-on mentorship through code reviews and architecture workshops, and solving hard problems that others cannot. The opportunity to position IRM as a strategic

differentiator rather than a traditional compliance function is exactly the type of groundbreaking work that excites me.

I would welcome the opportunity to discuss how my pharmaceutical analytics experience, technical architecture expertise, and track record of executive influence can contribute to IRM's mission of transforming risk management into a competitive advantage for Lilly. Thank you for your consideration, and I look forward to speaking with you.

Sincerely,

Matt Oremland, PhD